SEC Form 4 · accession 0001140361-18-001125
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacob Van Naarden
Officer — Chief Business Officer
Period of report
Jan 4, 2018
Accepted (ET)
Jan 5, 2018 · 7:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $84.88 | Jan 4, 2018 | A | 200,000 | A | — | Jan 3, 2028 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F11/24th of the Shares vest the second month anniversary following January 4, 2018 (the "Grant Date"), then an additional 1/48 vest monthly thereafter; provided however, that if the Company has not filed its next Registration Statement on Form S-8 by the first vesting date, then vesting will begin on the date that the Company files its next Registration Statement on Form S-8, but in any event no later than December 31, 2018 (the earlier of such dates, the "Filing Date"), with vesting from the Filing Date calculated based on 1/48th of the Shares per month, measured from the one-month anniversary of the Grant Date.